Bone Biologics Corporation, a company specializing in orthobiologic products for spine fusion markets, has successfully closed a public offering, raising $5.0 million. The offering included 1,250,000 shares of common stock, Series D warrants to purchase an equal number of shares, and Series E short-term warrants, all priced at $4.00 per share. The Series D warrants are exercisable immediately and expire in five years, while the Series E warrants also have immediate exercisability and expire in 18 months. H.C. Wainwright & Co. served as the exclusive placement agent for the offering. The funds raised will support clinical trials, patent portfolio maintenance, and general corporate purposes. If all warrants are exercised, additional proceeds could reach $10.0 million.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。